For research use only. Not for therapeutic Use.
UC2288（Cat No.:I015054） is a newly developed compound that acts as a p21 attenuator. It is cell-permeable, orally active, and shows relatively selective activity towards p21. Based on the structure of Sorafenib, UC2288 decreases p21 mRNA expression without dependence on p53, resulting in a reduction of p21 protein levels. Notably, UC2288 has minimal impact on p21 protein stability. Additionally, even at a concentration of 10 μM, UC2288 does not inhibit VEGFR2 and Raf kinases, distinguishing it from Sorafenib.
| Catalog Number | I015054 |
| CAS Number | 1394011-91-6 |
| Molecular Formula | C₂₀H₁₈ClF₆N₃O₂ |
| Purity | ≥95% |
| Target | MDM-2/p53 |
| IUPAC Name | 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[4-[5-(trifluoromethyl)pyridin-2-yl]oxycyclohexyl]urea |
| InChI | InChI=1S/C20H18ClF6N3O2/c21-16-7-4-13(9-15(16)20(25,26)27)30-18(31)29-12-2-5-14(6-3-12)32-17-8-1-11(10-28-17)19(22,23)24/h1,4,7-10,12,14H,2-3,5-6H2,(H2,29,30,31) |
| InChIKey | ISPSOOYSNVVMMB-UHFFFAOYSA-N |
| SMILES | C1CC(CCC1NC(=O)NC2=CC(=C(C=C2)Cl)C(F)(F)F)OC3=NC=C(C=C3)C(F)(F)F |
| Reference | [1]. Hiromi I Wettersten, et al. A Novel p21 Attenuator Which Is Structurally Related to Sorafenib. Cancer Biol Ther. 2013 Mar;14(3):278-85.<br>[2]. Romi Gupta, et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3062-71.<br>[3]. Jun Hyung Im, et al. p21 inhibitor UC2288 ameliorates MPTP induced Parkinson’s disease progression through inhibition of oxidative stress and neuroinammation. Translational Medicine.Neurobiology of Disease |
